Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission

Stanford University

Status and phase: Completed; Phase 2

Conditions: Leukemia, Myelocytic, Acute; Blood and Marrow Transplant (BMT); Leukemia

Treatments: Procedure: high dose chemotherapy then autologous hematopoietic cell transplant

Study type: Interventional

Funder types: Other

Identifiers

NCT00186381

BMT8N

77045

NCT00186381

Details and patient eligibility

About

Evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for AML.

Full description

To use high dose chemotherapy with autologous stem cell rescue to try to increase the chance of long term control and cure of the disease.

Enrollment: 200 estimated patients

Sex: All

Ages: 16 to 69 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:- must be in remission

• adequate organ function Exclusion Criteria:- prior MDS
• active infection
• liver disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)